Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5575926 | 0.90 | STS (0.57) | STSALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL5573839 | 0.88 | ALDH1A1 (0.58) | STSALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL5572863 | 0.88 | ALDH1A1 (0.55) | STSALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL5576735 | 0.88 | STS (0.51) | STSALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL5573773 | 0.87 | ALDH1A1 (0.49) | STSALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL5576153 | 0.86 | STS (0.49) | STSALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL4610832 | 0.86 | STS (0.49) | STSALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL4608779 | 0.85 | STS (0.49) | STSALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL28699743 | 0.83 | STS (0.49) | STSALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL4597915 | 0.82 | STS (0.52) | STSALDH1A1MAPTNPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | STS 4841/4885ALDH1A1 3484/4885MAPT 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.